Event

Aerosolized antibiotics are good treatment options for chronic pulmonary infection, particularly in cystic fibrosis and non-cystic fibrosis bronchiectasis. The goal of long-term inhalational antimicrobial agents is to suppress chronic bacterial infections and minimize cough, sputum production, and exacerbations of disease without the systemic toxicities. This session will review the current evidence supporting inhaled antibiotic use, guide clinicians on which patients may benefit, and the nuts and bolts and practical considerations regarding the initiation of aerosolized antibiotics.